Page 26 - Mylan EpiPen Teaching Note

EpiPen generates annual sales of $1to 1.5bn for Mylan.
But the company’s introduction of an alternative to this

higher cost primary product runs the risk of making it

obsolete and thereby reducing revenue flow and
company profitability even further.

Part of the problem is that Mylan will continue to receive

attention from both Congress and the FDA over its price

increases and the need to bring competition to the
market. It is notable that Mylan has not reduced the price

of EpiPen but rather increased it continually.